Mitigate the risk associated with aseptic fill finish manufacturing of biologics by partnering with a CMO demonstrating proven expertise in all aspects of biologics production. Learn more.
Updated study results show Moderna's coronavirus vaccine was strongly protective against COVID-19 through six months. But executives outlined contingency plans in case those effects fade.
The American Association for Cancer Research's virtual conference featured fresh data on a new kind of cell therapy, an emerging immunotherapy target and a KRAS reboot.
Regulators identified rare and serious blood clots in six women vaccinated with J&J's shot. The reaction resembles a side effect linked to AstraZeneca's vaccine.
Study results presented at AACR showed Retevmo shrank tumors in nine different cancers, building a case for the type of tissue-agnostic label that only three other medicines have secured.
Uncover how Life Science and Healthcare companies are earning customer trust with thoughtful digital experience management and data stewardship. Download whitepaper.
BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships.
BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries.
This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1255 23rd Street NW, Suite 550, Washington, DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.
0 Comments